Skip to main content
. Author manuscript; available in PMC: 2021 Nov 1.
Published in final edited form as: Cancer Res. 2021 Mar 8;81(9):2470–2480. doi: 10.1158/0008-5472.CAN-20-3232

Figure 2. Loss of each candidate gene maintains mTOR activity in response to PI3Kα inhibition.

Figure 2.

A. MCF7 cells stably expressing sgNT or sgRNA targeting individual candidate genes were treated with DMSO or 1μM alpelisib for 4hrs. Cell lysates were analyzed by immunoblotting for the indicated proteins.

B. MCF7 cells stably expressing sgNT or sgRNAs targeting DEPDC5, NPRL2, NPRL3 or STK11 were treated with various doses of AKT inhibitors (GDC0068, MK2206 and AZD5363) for 4 days. Cell viability was determined by CellTiter-Glo assay and IC50 (μM) were shown. Mean and SEM are shown; n=3 experiments. P-values were calculated using two-way ANOVA with Tukey’s post-hoc tests and statistical significance for the selected doses were shown next to IC50 values.